Cartesian Therapeutics (RNAC) Operating Income (2016 - 2025)
Historic Operating Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$21.1 million.
- Cartesian Therapeutics' Operating Income fell 1986.34% to -$21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.5 million, marking a year-over-year decrease of 7102.88%. This contributed to the annual value of -$43.9 million for FY2024, which is 4920.27% up from last year.
- Cartesian Therapeutics' Operating Income amounted to -$21.1 million in Q3 2025, which was down 1986.34% from -$21.8 million recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Operating Income peaked at $13.9 million during Q2 2022, and registered a low of -$36.3 million during Q4 2023.
- Its 5-year average for Operating Income is -$9.7 million, with a median of -$13.1 million in 2023.
- As far as peak fluctuations go, Cartesian Therapeutics' Operating Income soared by 296637.17% in 2022, and later crashed by 71707.32% in 2023.
- Quarter analysis of 5 years shows Cartesian Therapeutics' Operating Income stood at $4.1 million in 2021, then tumbled by 308.34% to -$8.5 million in 2022, then crashed by 327.64% to -$36.3 million in 2023, then increased by 26.43% to -$26.7 million in 2024, then increased by 21.19% to -$21.1 million in 2025.
- Its Operating Income was -$21.1 million in Q3 2025, compared to -$21.8 million in Q2 2025 and -$21.9 million in Q1 2025.